Wednesday, November 25, 2009, 3:20PM AEST - The Australian Stockmarket closes in 45 minutes.
To create a watchlist or portfolio of shares, Register

Allos Therapeutics, Inc. (ALTH)

8:00AM AEST: 6.35 USD  Up 0.19 (3.08%)  
 MORE ON ALTH 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Allos Therapeutics, Inc. (NGM:ALTH) Delayed quote dataEdit
Last Trade:6.35 USD
Trade Time: 8:00AM AEST
Change:Up 0.19 (3.08%)
Prev Close:6.16
Open:6.30
Bid:5.75 x 200
Ask:6.90 x 200
1y Target Est:12.67
Day's Range:6.16 - 6.35
52wk Range:4.68 - 9.30
Volume:1,853,594
Avg Vol (3m):2,984,940
Market Cap:660.03M
P/E (ttm):N/A
EPS (ttm):-0.77
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ALTH to Portfolio   Download Data

 HEADLINES 
Dow slips 17 points; Whiting Petroleum leads Colorado gainers
at bizjournals.com (Wed 9:05AM)
Healthcare Stocks: Safe and Speculative
TheStreet.com TV (Wed 12:30AM)
InPlay: Allos Therapeutics initiated with a Buy at ThinkEquity
Briefing.com (Tue 11:30PM)
Coverage initiated on Allos Therapeutics by ThinkEquity
Briefing.com (Tue 11:30PM)
[video] Healthcare Stocks: Safe and Speculative
at TheStreet.com (Tue 4:56AM)
A Big Upgrade for Allos Therapeutics
at Motley Fool (Tue 1:16AM)
Dow escapes deeper loss Wednesday; Gasco Energy leads Colorado gainers
at bizjournals.com (Thu, Nov 19)
Cramer's Stop Trading! Why Is Boeing Flying? (11/16/09)
at Seeking Alpha (Tue, Nov 17)
Cramer's 'Stop Trading!': Bristol-Myers
at TheStreet.com (Tue, Nov 17)
Cramer: Retail Investors Returning to Market?
at CNBC (Tue, Nov 17)
Stock Smackdown: Cramer vs. CAPS
at Motley Fool (Tue, Nov 17)
More Headlines for ALTH...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.78
EPS Est (in 2 years) (Dec-10) :-0.42
Avg Rec (current)*:1.9
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumula...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices